Aspen Pharma Faces European Pricing Probe

May 25, 2017

The European Commission has launched an antitrust investigation into South African manufacturer Aspen Pharma over excessive pricing concerns for cancer meds.

The probe will focus on five drugs Aspen acquired after patent expiration: chlorambucil, melphalan, mercaptopurine, tioguanine and busulfan.

According to the commission, Aspen threatened to withdraw the drugs from some markets in order to impose the price increases, and in some cases, followed through with the market withdrawl.

Read the FDA News coverage 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments